These data led us to investigate whether generating CD1c-retargeted allogeneic T cells recognizing mLPA expressed by leukemia cells might represent a novel immunotherapy able to overcome the limitation of conventional MHC-restricted T cell therapies for leukemia. Here, CD1C is linked to leukemia.